An Open-label, Multi-center Study to Compare the Relative Bioavailability of Tocilizumab in Healthy Subjects Following Single Dose Subcutaneous (SC) Administration Via Disposable Auto-Injector (DAI) Device Versus Pre-filled Glass Syringe (PFS)
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Roche
- 06 Jul 2012 Actual end date changed from 1 May 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov record.
- 21 May 2012 Actual patient number changed from 238 to 239 as reported by ClinicalTrials.gov.
- 15 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.